Weekly Recap | Gilead Sciences -4.82%, most brokers rate it buyWeekly Review·Sep 12 at 08:16 AMGILD+0.59%
Weekly Recap | Vertex Pharma -5.62%, low-volume pullback lags the S&P 500Weekly Review·Sep 12 at 07:06 AMVRTX+0.11%
Weekly Recap | Revolution Medicines -2.98%, consensus target above spotWeekly Review·Sep 12 at 06:40 AMRVMD+2.54%
Weekly Recap | Regeneron Pharma -5.59%, class action deadline passesWeekly Review·Sep 12 at 06:39 AMREGN+0.80%
Weekly Recap | Moderna -1.09%, tumour vaccine milestoneWeekly Review·Sep 12 at 06:22 AMMRNA+6.78%MRNY+4.36%
Weekly Recap | Illumina -5.39%, insider selling fuels valuation debateWeekly Review·Sep 12 at 06:07 AMILMN+4.46%
Weekly Recap | Vertex Pharma +0.82%, closing in on record highsWeekly Review·Sep 5 at 08:25 AMVRTX+0.11%
Weekly Recap | Regeneron Pharma +4.22%, closing in on record highsWeekly Review·Sep 5 at 07:49 AMREGN+0.80%
Weekly Recap | Moderna +5.48%, consensus target below spotWeekly Review·Sep 5 at 07:36 AMMRNA+6.78%MRNY+4.36%
Weekly Recap | Gilead Sciences +3.65%, FDA approves new HIV tabletWeekly Review·Sep 5 at 07:02 AMGILD+0.59%
Weekly Recap | Vertex Pharma -1.16%, most brokers rate it buyWeekly Review·Aug 29 at 06:39 AMVRTX+0.11%
